A medico-economic study of trabectedin compared with end-stage treatment in soft tissue sarcomas
| Autor: | Daniele Grazziotin-Soares, Johanne Daupin, Jean-Pierre Lotz, P Paubel |
|---|---|
| Přispěvatelé: | Institut Droit et Santé (IDS - U1145), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), General Agency for Equipment and Health Products, Groupe Hospitalier des Hôpitaux Universitaires de l’Est Parisien, Alliance Pour la Recherche En Cancérologie [CHU Tenon] (APREC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), Institut Droit et Santé ( IDS - U1145 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de pharmacie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Alliance Pour la Recherche En Cancérologie [CHU Tenon] ( APREC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), HAL-UPMC, Gestionnaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU) |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Cost effectiveness Context (language use) Economic [SDV.CAN]Life Sciences [q-bio]/Cancer Disease [ SDV.CAN ] Life Sciences [q-bio]/Cancer 03 medical and health sciences 0302 clinical medicine [SDV.CAN] Life Sciences [q-bio]/Cancer Internal medicine medicine 030212 general & internal medicine Stage (cooking) Trabectedin business.industry Health Policy Soft tissue sarcoma medicine.disease Confidence interval 3. Good health Surgery 030220 oncology & carcinogenesis Cost-effectiveness Sarcoma business Soft-tissue-sarcoma medicine.drug |
| Zdroj: | Journal of Cancer Policy Journal of Cancer Policy, 2017, 12, pp.55-60. ⟨10.1016/j.jcpo.2017.03.011⟩ Journal of Cancer Policy, 2017, 12, pp.55-60. 〈10.1016/j.jcpo.2017.03.011〉 Journal of Cancer Policy, Elsevier, 2017, 12, pp.55-60. ⟨10.1016/j.jcpo.2017.03.011⟩ |
| ISSN: | 2213-5383 |
| DOI: | 10.1016/j.jcpo.2017.03.011⟩ |
| Popis: | International audience; The development of new anticancer drugs has strongly contributed to improve patients’ outcomes. However, the question can be raised whether the sometimes minor benefits are worth the cost to both the individuals and the society. The aim of this medico-economic study was to evaluate trabectedin cost-effectiveness compared with end-stage care in the treatment of soft-tissue sarcoma. We retrospectively analyzed data from 45 patients treated with trabectedin for soft tissue sarcoma. Real-life data of clinical benefits and costs of trabectedin were compared with simulated end-stage treatment. Univariate and probabilistic sensitivity analyses identified key drivers of the incremental cost-effectiveness ratio. Trabectedin was associated with longer progression-free survival (4.0 months versus 1.6 months) and higher costs (€24,780 versus €15,490) compared with end-stage treatment. The incremental cost per year of progression-free survival gained with trabectedin was €46,104 (95% confidence interval; €45,039–€47,169). The results were relatively insensitive to changes. Trabectedin was cost-effective in the context of an orphan disease, when used to treat patients with a short life expectancy and few therapeutic options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect